GSK and Yale Partner to Work on New Class of Drugs

UK drug maker GlaxoSmithKline (GSK) has partnered up with US Yale University under a collaboration that will concentrate on creating a possible new class of drugs. Under the discovery agreement, GSK’s scientists will work alongside Yale researchers to build on Yale’s pioneering work with so-called proteolysis targeting chimeric molecules (PROTACs).

Continue Reading